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Aim:  Intranasal  aerosol  administration  of  drugs  is  widely  used  by  ENT  specialists.  Although
clinical evidence  is  still  lacking,  intranasal  nebulization  appears  to  be  an  interesting  therapeu-
tic option  for  local  drug  delivery,  targeting  anatomic  sites  beyond  the  nasal  valve.  The  sonic
nebulizer NL11SN  associates  a  100  Hertz  (Hz)  sound  to  the  aerosolization  to  improve  deposi-
tion in  the  nasal/paranasal  sinuses.  The  aim  of  the  present  study  was:  to  evaluate  in  vivo  the
inﬂuence of  associating  a  100  Hz  sound  on  sinus  ventilation  and  nasal  and  pulmonary  aerosol
deposition  in  normal  volunteers,  and;  to  quantify  in  vitro  aerosol  deposition  in  the  maxillary
sinuses in  a  plastinated  head  model.
Material  and  methods:  Scintigraphic  analysis  of 81mKr  gas  ventilation  and  of  sonic  aerosolRhinosinusitis
(99mTc-DTPA)  deposition  using  the  NL11SN  was  performed  in  vivo  in  seven  healthy  volunteers.
In parallel,  NL11SN  gentamicin  nebulization  was  performed,  with  or  without  associated  100  Hz
sound, in  a  plastinated  human  head  model;  the  gross  amount  of  gentamicin  delivered  to  the
paranasal sinuses  was  determined  by  ﬂuorescence  polarization  immunoassay.
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Results:  Associating  the  100  Hz  sound  to 81mKr  gas  ensured  paranasal  sinus  ventilation  in  healthy
volunteers. 99mTc-DTPA  particles  nebulized  with  the  NL11SN  were  deposited  predominantly
in the  nasal  cavities  (2/3,  vs  1/3  in  the  lungs).  In  vitro,  the  use  of  NL11SN  in  sonic  mode
increased gentamicin  deposition  threefold  in  the  plastinated  model  sinuses  (P  <  0.002);  the
resulting antibiotic  deposit  would  be  sufﬁcient  to  induce  a  local  therapeutic  effect.
Conclusion:  The  NL11SN  nebulizer  ensured  preferential  nasal  cavity  aerosol  deposition  and
successfully  targeted  the  maxillary  sinuses.





































Although  the  efﬁcacy  of  nebulizing  pulmonary  antibiotics
and  corticosteroids  has  been  demonstrated  in  many  studies
[1,2],  nebulization  of  antibiotics  with  a  nasal  target  remains
controversial  [3,4]. The  French  health  products  safety
agency  (Afssaps)  does  not  recognize  any  indication  for  local
antibiotics  in  rhinosinus  pathology  [5].  In  theory,  however,
nebulization  has  the  advantage  over  classic  administration
routes  of  delivering  the  drug  directly  to  the  target  organ,
thereby  avoiding  systemic  side  effects  while  increasing  the
local  dose.  Consequently,  despite  a  relative  lack  of  clinical
evidence  and  the  small  number  of  published  studies,  nasal
nebulization  is  in  fact  frequently  used  by  ENT  specialists  and
by  general  practitioners  [6,7]. Nasal  aerosol  therapy  is  used
in  most  acute  and  chronic  nasal  cavity  and  sinus  patholo-
gies,  enabling  direct  application  to  the  rhinosinusal  mucosa,
with  a  rapid  clinical  response  and  minimal  side  effects.  It  is
particularly  used  in  the  case  of  failure  of  reference  per  os
or  spray  treatment  [6,8]. Nebulization  may  indeed  be  an
interesting  treatment  option  in  nasal  antibiotherapy  [9,10].
There  are  currently  no  nasal  antibiotic  sprays;  sprays,
moreover,  fail  to  target  potentially  infected  anatomic
sites  such  as  the  maxillary  sinus,  ethmoid  cells  or  middle
turbinate  [11,12].  As  nebulizers  produce  ﬁner  particles  than
sprays  (4  m  vs  30  m),  they  can  target  anatomic  areas
beyond  the  nasal  valve,  but  still  fail  to  reach  the  maxil-
lary  sinuses.  Associating  a  100  Hz  acoustic  wave,  however,
enhances  ventilation  [13]  and  aerosol  deposition  [14]  in  the
sinonasal  cavities.  Nasal  sonic  nebulizers  may  thus  be  able
to  generate  the  best-adapted  aerosols  for  local  treatment
of  rhinosinusitis.
The  present  study  sought  to  quantify  respiratory  pathway
and  maxillary  sinus  deposition  of  the  aerosol  produced  by  a
nasal  sonic  nebulizer,  NL11SN  (DTF,  Saint-Étienne,  France)
designed  to  optimize  nasal  cavity  and  maxillary  sinus  deposi-
tion  by  associating  a  100  Hz  sound  to  the  aerosol  [15]. Results
with  the  system  are  reported  in  vivo  in  healthy  volunteers,
using  a  radioactive  tracer,  and;  in  vitro  with  gentamicin  in  a
plastinated  human  head  model.
Material and methods
Nasal  sonic  nebulizerNebulization  used  an  ATOMISOR  NL11SN  (NL11SN)  nasal
sonic  nebulizer  with  an  ATOMISOR  AOHBOX® compres-
sor  (DTF  Médical,  Saint-Étienne,  France).  The  aerosol
•
•as  administered  via  a  C28E  nasal  plug  (DTF  Médical,
aint-Étienne,  France).
ealthy  volunteer  scintigraphy  study
tudy  population
his  single-center  study  included  seven  healthy  male,  non-
moking  volunteers  aged  21  to  36  years,  with  a  mean  (±  SD)
eight  of  181  ±  3  cm  and  a  mean  weight  (±  SD)  of  77  ±  10  kg.
The  study  design  was  approved  by  the  ethics  committee
f  the  Saint-Luc  University  Clinics  of  the  Catholic  University
f  Louvain  (UCL,  Belgium),  where  the  study  was  performed.
n  line  with  the  Declaration  of  Helsinki  and  good  clinical
ractice  guidelines,  the  healthy  volunteers  signed  written
nformed  consent  before  ﬁnal  inclusion.
The  subjects  were  judged  healthy  at  the  ﬁrst  selection
onsultation  after  a complete  medical  check-up  comprising
hysical  examination,  vital  signs  assessment,  medical  and
urgical  history  and  inclusion/exclusion  criteria:  the  pul-
onary  scintigraphy  examination  required  subjects  to  be
quivalent  in  gender,  age,  height  and  weight  so  as  to  limit
nd  harmonize  thoracic  tissue  attenuation  within  the  study
opulation.
The  main  grounds  for  exclusion  were  history  of  car-
iovascular  pathology,  allergy,  asthma  or  other  pulmonary
athology  or  any  ENT,  and  especially  rhinosinusal,  pathol-
gy  (polyposis  or  any  type  of  rhinosinusitis)  or  ENT  or  head
nd  neck  surgery  (whether  repair  or  functional).
The  clinical  examination  was  completed  by  nasal  cavity
hinoscopy;  subject  3  showed  right  nasal  deviation  and  sub-
ect  5  a  right  septal  spur,  but  these  were  considered  to  be
natomic  variants  not  entailing  exclusion.
cintigraphic  ventilation  study  of  the  contribution  of  a
00  Hz  sound
rypton-81  m  (81mKr)  ventilation  was  performed  to  study  the
ffect  on  maxillary  sinus  penetration  of  associating  a  100  Hz
ound  and  to  determine  the  anatomic  upper  airway  and  lung
egions. 81mKr  gas  (81Rb/81mKr  generator,  Covidien,  Petten,
he  Netherlands)  was  continuously  administered  via  nasal
lugs  to  achieve  upper  and  lower  airway  ventilation.
The  following  2-min  scintigraphic  acquisitions  were  per-
ormed  using  a  STARPORT  400  AC/T  gamma  camera  (General
lectric,  Horsholm,  Denmark):Gas-1:  nasal  cavities  on  right  lateral  head  view;
































































































 Gas-3: nasal  cavities  on  AP  head  view  on  ventilation  with
100  Hz  sound;
Gas-4: lungs  on  posterior  thorax  view.
onic 99mTc-DTPA  aerosol  deposition  study
he  NL11SN  nebulizer  was  loaded  with  a  3  ml  solution
ontaining  25  mg  DTPA  (diethylene-triamine  penta-acetic
cid)  with  74  MBq  Technetium-99  m  (99mTc)  tracer  (TechneS-
an  DTPA,  Mallinckrodt  Medical,  Petten,  The  Netherlands).
Ahead  of  the  aerosol  session,  subjects  were  trained  to
nhale  the  aerosol  by  the  nose  and  breathe  out  by  the  mouth.
n  absolute  ﬁlter  system  (BB50TE,  Pall  Medical,  France)
rotected  the  ambient  air  and  quantiﬁed  exhaled  aerosol
ctivity.  Nebulization  was  associated  to  a  100  Hz  sound  for
0  minutes.
Immediately  after  inhalation,  the  subject  sat  face  to  the
amera  for  three  acquisitions:
Aerosol-1:  nasal  cavities  on  right  lateral  head  view;
Aerosol-2:  thorax  on  posterior  view;
Aerosol-3:  residual  nebulizer  and  accessory  activity.
mage  processing
otal  deposited  airway  activity  was  calculated  on  the
ctivity-balance  method,  consisting  in  subtracting  non-
eposited  activity  from  the  activity  initially  introduced  in
he  nebulizer.  Results  were  corrected  for  background  noise
nd  radioactive  decay.
Regions  were  traced  around  the  anatomic  areas  of  inter-
st  (nasal  cavities,  lungs,  stomach)  from  the  ventilation
mages  and  applied  to  each  deposition  image.  Percentage
erosol  deposition  per  region  of  interest  was  calculated  from
he  total  deposited  activity.  Deposited  DTPA  mass  (g)  was
lso  determined  for  each  region  from  the  DTPA  mass  initially
ntroduced  in  the  nebulizer.
n  vitro  gentamicin  sonic  aerosol  deposition  study
ntrasinus  concentrations  of  an  antibiotic,  gentamicin,  neb-
lized  with  and  without  associated  100  Hz  sound,  were
ompared  in  a  plastinated  head  anatomic  model.
lastinated  head  anatomic  model
he  human  head  plastination  technique  developed  and
dapted  for  ENT  modeling  in  the  anatomy  laboratory  of  the
aint-Étienne  Medical  School  (France)  was  used  to  create
everal  plastinated  specimens,  three  of  which  were  dedi-
ated  to  functional  sinonasal  cavity  studies  [16,17].
The  plastinated  anatomic  specimens  were  obtained
ollowing  the  usual  stages  of  this  technique:  specimen
reparation  (3  days),  formaldehyde  ﬁxation  (3  months),
ehydration  and  degreasing  with  acetone  (1—2  months),  sil-
cone  impregnation  (10—20  days),  and  polymerization  (2—3
onths).  The  polymerization  was  optimized  to  avoid  tissue
etraction  [17]. The  plastinated  heads  were  validated  as
erosol  deposition  models  after  anatomic,  geometric  and
erodynamic  analysis,  using  classical  clinical  techniques:
hinoscopy,  endoscopy,  CT,  rhinomanometry  and  acoustic
hinometry.
The  models’  maxillary  sinuses  were  opened  using  a
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lexiglass  plates  were  used  to  close  the  sinuses  hermeti-
ally  during  nebulization  (Fig.  1).  This  gave  access  to  the
inus  antrum  to  collect  the  deposited  aerosol.
entamicin  nebulization
entamicin  (Gentallin®, Schering-Plough  SAS,  Courbevoie,
rance),  an  aminoglycoside  active  on  Gram-negative  bacte-
ia  and  staphylococci,  with  recognized  efﬁcacy  on  bacteria
mplicated  in  rhinosinusitis  [18,19], was  chosen  as  marker
or  its  robustness  and  speciﬁc  deposition  using  routine  meth-
ds.  Two  concentrations  were  used  for  the  aerosol  solution:
0  and  80  mg/ml.
The  NL11SN  nebulizer  was  loaded  with  4  ml  gentamicin
nd  connected  to  the  model  nostrils  via  nasal  plugs  (Fig.  1).
Nebulization  lasted  10  minutes.  The  Plexiglass  plates
ere  then  withdrawn  and  the  maxillary  sinuses  were  given
our  rinses  of  1  ml  physiological  saline  by  syringe  to  collect
he  gentamicin  deposited  on  the  sinus  walls.  The  collected
iquid  was  kept  at  —20 ◦C  for  subsequent  measurement  of
he  collected  gentamicin.
After  each  nebulization,  the  specimen  was  liberally
ashed  and  dried  in  free  air  for  at  least  48  hours.
Nebulizations  (n  =  112)  were  performed  either  in  sonic
ode  (with  100  Hz  sound)  or  classical  mode  (without  sound).
hysiological  saline  nebulizations  (n  =  34)  were  used  to  check
ash-out:  i.e.,  that  no  gentamicin  remained  in  the  sinuses.
entamicin  assay
entamicin  was  assayed  on  291  sinus  rinse  liquid  samples
y  immuno-enzymatic  analysis  (ﬂuorescence  polarization
mmunoassay)  on  a  TDX/FLX® device  (Abbott  Diagnostics,
ungis,  France).  Assays  were  performed  in  triplicate  using
entamicin® reagents  (Abbott  Laboratories,  Diagnostic  Divi-
ion,  EU)  with  sensitivity  of  0.27  mg/L.
tatistical  analysis
he  impact  of  a  100  Hz  sound  on  gentamicin  sinus  deposi-
ion  in  the  plastinated  head  model  was  assessed  by  t  test
XLSTATS®).  The  signiﬁcance  threshold  was  set  at  P  <  0.05.
esults
he  in  vivo  inhalation  sessions  (81mKr  ventilation  and 99mTc-
TPA  nebulization)  were  well  tolerated  by  all  subjects,  and
here  were  no  adverse  events.  The  upper  and  lower  air-
ays  could  be  visualized  with  the 81mK  gas  in  all  cases.  The
ecorded  images  testiﬁed  to  a  positive  impact  on  maxillary
inus  penetration  of  associating  the  100  Hz  sound  to  venti-
ation  (Fig.  2,  Gas-2  and  Gas-3).
The  images  also  enabled  anatomic  regions  to  be  deﬁned
n  the  upper  airways  and  lungs,  so  as  to  quantify  sonic
erosol  deposition  of  nasally  inhaled 99mTc-DTPA  (Fig.  2,
erosol-1).
In  terms  of 99mTc-DTPA  mass,  respiratory  pathway  aerosol
istribution  was  2,400  ±  475  g  in  the  upper  airways  (nasal
avities  and  rhinopharynx)  and  925  ±  425  g  in  the  lungs,
emonstrating  effective  targeting  of  the  nasal  cavities  (two-
hirds  of  the  activity)  as  compared  to  the  lungs.  These  upper
irway  calculations  took  account  of  swallowing  and  nasal
learance  (Table  1).
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Figure  1  Nebulization  of  gentamicin  in  a  plastinated  head  model,  using  the  ATOMISOR  NL11SN  nasal  sonic  nebulizer  connected  to
an ATOMISOR  AOHBOX® compressor.
The pressure  input  tube  ensured  continuous  compressed  air  inﬂow  and  the  sound  input  tube  ensured  conduction  of  the  100  Hz  sound
produced by  the  compressor.  The  sonic  nebulizer  was  connected  to  
plexiglass plates  on  either  side  of  the  model  hermetically  closed  ext
Table  1 99mTc-DTPA  aerosol  deposit  (g)  from  NL11SN
nebulizer/AOHBOX® compressor,  in  seven  healthy  subjects
(mean  ±  SD).
Upper  airwaysa 2,400  ±  475
Lungs 925  ±  425

































ca Upper airways taking account of nasal cavities, rhinopharynx
and stomach.
The  images,  however,  showed  only  a  small  amount  of
aerosol  in  the  maxillary  sinuses,  far  less  than  the  krypton
gas  seen  to  penetrate  them  under  ventilation  scintigraphy.
Valid  image  processing  to  quantify  maxillary  region  aerosol
deposition  precisely  was  not  feasible  due  to  the  difﬁculty  of
delineating  the  anatomical  sites  precisely.
Little  radioactive  DTPA  (0  ±  25  g)  was  found  in  the  stom-
ach,  indicating  that  little  aerosol  was  swallowed  during  the
nebulization  session.
In  vitro,  the  112  gentamicin  nebulizations  and  itera-
tive  rinsing  did  not  affect  the  plastinated  head  anatomy.
Absence  of  gentamicin  in  the  sinuses  was  checked  by
assaying  the  sinusal  liquid  collected  after  physiological
saline  (result:  <  0.27  mg/l).
The  results  detailed  in  Table  2  show  an  up  to  3-fold
increase  (P  <  0.05)  in  gentamicin  concentration  in  the  max-
illary  sinuses  when  the  100  Hz  sound  was  associated  to
nebulization,  for  both  types  of  concentration  tested.  Deposi-
tion  was  signiﬁcantly  greater  in  the  left  than  the  right  sinus,
with  or  without  associated  sound  (P  <  0.05).
Discussion
The  interest  of  associating  a  100  Hz  sound  to  nasal  admin-
istration  was  studied  ﬁrst  directly  in  healthy  volunteers  by
in  vivo 81mKr  ventilation  scintigraphy.  The  gas  was  delivered
nasally  by  an  NL11SN  nebulizer,  and  nasal  cavity  ventila-
tion  was  recorded  laterally  before  and  during  the  addition
w
a
tthe  plastinated  head  nostrils  via  nasal  plugs.  The  two  movable
ernal  access  to  the  maxillary  sinuses.
f  sound.  The  images  (Fig.  2,  Gas-2  and  Gas-3)  display  the
mpact  of  associated  100  Hz  sound  on  maxillary  sinus  pene-
ration,  enhancing  ventilation  with  increased  gas  exchange
etween  nasal  cavities  and  maxillary  sinuses.
A  drug  aerosol,  however,  may  show  different  aerody-
amic  behavior  from  a  gas,  with  consequently  varying
mpact  of  100  Hz  acoustic  vibrations.  The  airway  distri-
ution  of  the  nasally  inhaled  sonic  aerosol  was  therefore
tudied  using 99mTc-DTPA  as  radioactive  tracer.  The  mass  of
9mTc-DTPA  deposited  in  the  upper  airways  and  lungs  was
alculated  for  anatomic  regions  deﬁned  on  the  ventilation
mages.  Two-thirds  of  the  sonic 99mTc-DTPA  aerosol  was  dis-
ributed  in  the  upper  airways,  and  one-third  in  the  lungs.
ithin  the  nasal  cavities,  aerosol  deposition  stretched  from
he  nasal  vestibule  to  the  pharynx  (Fig.  2,  Aerosol-1),  rather
han  being  restricted  to  the  ﬁrst  centimeters  of  the  nasal
ossae  as  usually  described  in  the  literature  [11], which
mplies  that  it  passed  through  the  middle  and  inferior  nasal
eati.
This  in  vivo  study,  however,  involved  limitations,  one
ethodological  and  the  other  related  to  the  use  of  healthy
ubjects.  The  methodology  provided  only  overall  quan-
iﬁcation  of  upper  airway  deposition,  without  detailed
ifferentiation  of  deposition  in  therapeutic  target  sites  such
s  the  maxillary  sinuses.  The  proximity  of  the  maxillary
inuses  to  the  nasal  fossae  makes  precise  localization  within
he  upper  airways  as  a  whole  difﬁcult  [17,20], especially
ue  to  the  Compton  effect.  This  means  that  the  theoretical
ffectiveness  of  the  target  deposition  cannot  be  assessed
ith  full  accuracy.  Moreover,  the  healthy  volunteers  them-
elves  represented  a  limitation  to  the  study  of  the  targeting
f  areas  of  therapeutic  interest,  as  their  maxillary  ostia  were
pen  (as  seen  on 81mKr  ventilation)  unlike  in  the  general  case
f  patients  with  rhinosinusal  pathology:  patients  likely  to  be
oncerned  by  nasal  antibiotherapy  for  chronic  rhinosinusitis
ill  generally  have  (a)  closed  ostium  (a)  [21].
The  second,  in  vitro,  study  examined  the  effect  of
ssociating  a  100  Hz  sound  to  a  gentamicin  aerosol  in  a  plas-
inated  human  head  model.  Plastination  provides  a  model
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Table  2  Mean  gentamicin  concentration  (mg/l)  collected  from  the  left  and  right  maxillary  sinuses  of  the  plastinated  head  model
after classic  nebulization  (without  associated  sound)  and  sonic  nebulization  (with  associated  100  Hz  sound)  for  two  antibiotic





Gentamicin  concentration  collected
in maxillary  sinuses  (mg/l)
Right  sinus Left  sinus
40 Classic  <  0.27a <  0.27  P  =  0.679**
40 Sonic 0.64  ±  0.22  0.73  ±  0.32  P  =  0.242**
P  =  0.002* P  =  0.005*
80 Classic 0.63  ±  0.52 1.19  ±  1.03 P  =  0.005**
80 Sonic 1.35  ±  0.91 2.33  ±  1.49 P  =  0.019**
P  <  0.0001* P  <  0.0001*






































































et test, classic vs. sonic nebulization.
** t test, right vs. left sinus.
onserving  the  mucosa,  anatomy  and  aerodynamics  of  the
asal  cavities  and  sinuses.  Moreover,  the  active  substances
ebulized  and  deposited  in  the  maxillary  sinuses  can  be
ssayed  in  situ.
The  results  demonstrated  that  the  gentamicin  nebu-
ized  by  the  NL11SN  penetrated  and  was  deposited  in  the
odel’s  maxillary  sinuses.  The  main  factor  affecting  sinusal
eposition  was  the  100  Hz  sound,  in  presence  of  which  the
entamicin  concentration  collected  from  the  sinuses  was
igniﬁcantly  increased,  by  a  factor  of  1.6  to  3  (Table  2).  For  a
iven  gentamicin  dose,  the  increase  in  sinus  deposition  was
quivalent  in  the  two  sinuses,  although  the  absolute  amount
f  deposit  was  signiﬁcantly  different  between  the  two
P  <  0.05),  probably  due  to  geometrical  differences  between
he  left  and  right  maxillary  sinus  ostia.  Rhinomanometric
easurements  taken  on  the  same  model  showed  greater
esistance  in  the  right  than  in  the  left  ostium  [17,22]. The
ain  in  maxillary  gentamicin  deposition  provided  by  the  asso-
iated  sound  was  independent  of  ostium  geometry.
Although  the  model  enabled  sinus  deposits  to  be  col-
ected,  it  involved  certain  limitations.  The  gentamicin  assay
esults  were  highly  variable,  due  to  the  technical  difﬁculty
f  rinsing  the  sinuses  with  physiological  saline  to  collect  the
entamicin.  However,  well  controlled,  the  technique,  sinus
ntrum  anatomy  and  the  uneven  aerosol  deposition  over  the
avities  meant  that  collection  was  neither  exhaustive  nor
trictly  reproducible  from  one  trial  to  another.
Moreover,  sinus  rinsing  was  suboptimal,  as  it  included
either  the  lateral  wall  of  the  maxillary  sinus  nor  any  possi-
le  physical  gentamicin  absorption  by  the  plastinated  sinus
ucosa;  the  real  quantity  of  deposited  gentamicin  in  the
inuses  was  therefore  once  again  inevitably  underestimated.
There  was  a  further  technical  limitation  in  as  much
s  the  plastinated  head  specimen  was  not  ventilated
nd  thus,  was  ‘‘passive’’  under  aerosol  administration.
nhalation  and  exhalation  of  the  aerosolized  particles  was
ot  reproduced,  which  may  have  affected  the  deposition
inetics  as  compared  to  a  ventilated  model.  This  lack  of
‘respiration’’  might  reduce  or  on  the  contrary  increase
inus  penetration:  the  former,  as  airﬂow  through  the  nasal
avities  under  inspiration  (acceleration)  and  expiration  (vor-




The  nasal  cavities  (sinus  respiration)  [21,22]; or  the  latter,
ue  to  aerosol  accumulation  in  the  nasal  fossae,  increasing
enetration  into  the  maxillary  sinuses  via  the  ostia.
Nasal  antibiotic  nebulization  is  especially  controversial
ue  to  a lack  of  data  as  to  the  quantity  of  active  molecules
ctually  deposited,  their  potential  clinical  efﬁcacy  and  the
xpected  therapeutic  doses.
The  present  in  vivo  results  in  healthy  subjects  and  in  vitro
esults  in  the  plastinated  model  showed  the  NL11SN  sonic
ebulizer  to  be  suitable  for  targeting  the  upper  airways,
ncluding  the  sinus  cavities.
The  plastinated  head  model  could  be  useful  for  initial
ssessment  of  the  theoretic  efﬁcacy  of  an  antibiotic  deposit
n  the  maxillary  sinuses  according  to  the  quantities  of  active
ubstance  collected.  In  the  present  study,  a  mean  1.35  mg/L
nd  2.33  mg/L  were  measured  in  the  rinse  liquid  from  the
ight  and  left  sinuses  respectively,  corresponding  to  a  mean
ass  of  3.31  g  collected  from  the  sinuses.
In  terms  of  deposition  efﬁcacy,  it  is  possible  to  esti-
ate  whether  the  quantity  of  deposited  gentamicin  was
ufﬁcient  to  ensure  a local  therapeutic  effect.  Sinus  gen-
amicin  deposition  can  be  compared  to  the  recognized
ffective  pulmonary  deposition  of  a  reference  aminoglyco-
ide  by  normalizing  deposition  per  unit  tissue  area.  Among
he  aminosides  used  in  nebulization,  tobramycin  (TOBI®)
hows  recognized  efﬁcacy  in  Pseudomonas  aeruginosa  pul-
onary  infection  in  cystic  ﬁbrosis  patients.  In  vivo  studies
eported  about  45  mg  tobramycin  deposited  in  the  lungs
sing  the  reference  pneumatic  nebulizer  [1].
From  these  data,  the  tobramycin  deposition  rate  in  the
ungs  can  be  estimated  at  0.0346  g/cm2 (for  a  maximum
eposition  area  of  130  m2).
If  the  maxillary  sinus  is  assimilated  to  a  sphere  of  about
7  cm3 (mean  =  15  to  20  cm3 in  the  literature)  [23—25], the
otential  aerosol  deposition  area  in  a  sinus  will  be  31.9  cm2.
entamicin  deposition  in  the  plastinated  head  sinuses  was
stimated  at  0.05183  g/cm2.
According  to  these  new  data,  the  quantity  of  gentamicin
eposition  in  the  in  vitro  model  sinuses  can  be  estimated  as
eing  1.5  fold  greater  (0.05183  g/cm2 vs.  0.0346  g/cm2)
han  the  reference  aminoglycoside  deposition  in  the  lungs.
hus,  on  this  initial  approach,  the  quantity  of  gentamicin
Sonic  aerosol  therapy  to  target  maxillary  sinuses  
Figure  2  Scintigraphy  images  in  healthy  volunteers,  using  the
NL11SN  sonic  nebulizer  and  ATOMISOR  AOHBOX® compressor:
Aerosol-1: 99mTc-DTPA  aerosol  deposition  with  associated  100  Hz




























Rwithout  associated  sound  (anterior  side  of  the  nasal  cavities);
Gas-3: 81mKr  ventilation  with  associated  100  Hz  sound  (anterior
side of  the  nasal  cavities).
collected  from  the  maxillary  sinuses  would  seem  to  be  sufﬁ-
cient  to  induce  a  local  antibiotic  effect.  These  results  should
be  conﬁrmed  in  a  clinical  assessment  of  the  therapeutic
efﬁcacy  of  antibiotic  deposition  by  nasal  sonic  aerosol.249
onclusions
he  present  study  showed  that  sonic  nebulization  (i.e.,  neb-
lization  coupled  to  a  100  Hz  sound),  as  implemented  using
he  NL11SN  nebulizer,  optimized  aerosol  deposition  in  the
asal  cavities  (two-thirds  of  activity)  and  effectively  tar-
eted  anatomic  regions  of  interest  such  as  the  maxillary
inuses.  Maxillary  sinus  penetration  proves  passage  through
he  middle  meatus,  the  center  of  sinus  pathology.  Thus  the
asal  sonic  aerosols  produced  by  the  NL11SN  can  treat  cer-
ain  rhinosinus  pathologies.
By  comparison  with  the  results  for  pulmonary  deposi-
ion  normalized  per  unit  of  tissue  surface,  the  amount  of
inus  drug  deposition  seems  sufﬁcient  to  induce  a  local  anti-
nfection  effect.  The  plastinated  human  head  seems  to  be  a
seful  model  for  the  assessment  of  the  theoretical  therapeu-
ic  efﬁcacy  of  sinus  deposition  of  drugs,  and  of  antibiotics
n  particular.  The  results  show  that  antibiotic  nebulization
y  the  nasal  route  may  be  useful,  avoiding  acquisition  of
esistance.
Clinical  studies  will  be  required  to  validate  the  treat-
ent  efﬁcacy  of  nebulized  deposition  of  antibiotics  or
ther  molecules  using  the  NL11SN  sonic  nebulizer  in
arious  rhinosinusal  pathologies  (infectious  and/or  inﬂam-
atory),  in  order  to  determine  their  potential  clinical
pplications.
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